FcγRIV : A novel FcR with distinct IgG subclass specificity

By F. Nimmerjahn, P. Bruhns, Kentaro Horiuchi, J. Ravetch. 2005

657 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/e45ef06c10ad7e30ce12d0e068a44cc61f60ca05

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. James P. Allison
2. J. Wolchok
3. Sergio A. Quezada
4. K. Peggs
5. H. Yagita
6. J. Ravetch
7. Lieping Chen
8. F. Nimmerjahn

In Molecular Biology

1. Kentaro Shimizu
2. J. Ravetch
3. J. Wolchok
4. F. Nimmerjahn

In Radiology, Nuclear Medicine and Imaging

1. J. Ravetch
2. F. Nimmerjahn

Citations in the corpus

• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma (2013, background): “In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
• IgEb immune complexes activate macrophages through FcγRIV binding (2007, background): “FcγRIV is encoded by the gene Fcgr4 (also called Fcgr3a , Fcrl3 and CD16-2”